Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating reissued by analysts at Bank of America Corporation in a research note issued on Monday. They currently have a $36.00 price target on the biotechnology company’s stock, up from their previous price target of $34.00. Bank of America Corporation’s target price suggests a potential upside of 5.14% from the stock’s previous close.

Several other brokerages also recently weighed in on ASND. Wells Fargo & Company reaffirmed a “buy” rating and set a $51.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. Credit Suisse Group set a $28.00 target price on shares of Ascendis Pharma A/S and gave the stock a “buy” rating in a research note on Tuesday, July 18th. TheStreet downgraded shares of Ascendis Pharma A/S from a “c-” rating to a “d” rating in a research note on Thursday, June 15th. Leerink Swann reaffirmed a “hold” rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $10.71 target price (down from $65.00) on shares of Ascendis Pharma A/S in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $33.67.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded up 8.134% during trading on Monday, hitting $37.025. 243,221 shares of the stock were exchanged. Ascendis Pharma A/S has a one year low of $17.15 and a one year high of $42.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $0.78 million. During the same quarter in the prior year, the company posted ($0.53) earnings per share. The business’s revenue was down 61.4% compared to the same quarter last year. Equities research analysts forecast that Ascendis Pharma A/S will post ($0.12) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/ascendis-pharma-as-asnd-given-buy-rating-at-bank-of-america-corporation/1587503.html.

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its position in shares of Ascendis Pharma A/S by 23.6% in the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,020 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Ascendis Pharma A/S by 7.9% in the 2nd quarter. Alps Advisors Inc. now owns 29,264 shares of the biotechnology company’s stock valued at $812,000 after purchasing an additional 2,144 shares during the last quarter. Bank of Montreal Can increased its position in shares of Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,541 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $144,000. Finally, Karp Capital Management Corp purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $203,000. 71.60% of the stock is currently owned by institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.